Academic Journal
Evolution of male breast cancer treatment: Results from twenty years of BreastSurgANZ Quality Audit data.
| Τίτλος: | Evolution of male breast cancer treatment: Results from twenty years of BreastSurgANZ Quality Audit data. |
|---|---|
| Συγγραφείς: | Kinsey-Trotman S; School of Medicine, Robinson Research Institute, College of Health, Adelaide University, Adelaide, SA, 5005, Australia; The Queen Elizabeth Hospital, Central Adelaide Local Health Network, 28 Woodville Rd, Woodville South, SA, 5011, Australia. Electronic address: steve.kinsey-trotman@adelaide.edu.au., Walters D; The Queen Elizabeth Hospital, Central Adelaide Local Health Network, 28 Woodville Rd, Woodville South, SA, 5011, Australia., Bierton C; Lyell McEwin Hospital, Northern Adelaide Local Health Network, Haydown Rd, Elizabeth Vale, SA, 5112, Australia., Edwards S; School of Public Health, Adelaide University, Adelaide, SA, 5005, Australia., Dasari P; School of Medicine, Robinson Research Institute, College of Health, Adelaide University, Adelaide, SA, 5005, Australia., Ingman WV; School of Medicine, Robinson Research Institute, College of Health, Adelaide University, Adelaide, SA, 5005, Australia; The Queen Elizabeth Hospital, Central Adelaide Local Health Network, 28 Woodville Rd, Woodville South, SA, 5011, Australia. |
| Πηγή: | Breast (Edinburgh, Scotland) [Breast] 2026 Oct; Vol. 89, pp. 104887. Date of Electronic Publication: 2026 Jul 24. |
| Τύπος έκδοσης: | Journal Article; Observational Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2002- : Amsterdam : Elsevier Original Publication: Edinburgh ; New York : Churchill Livingstone, c1992- |
| Ιατρικοί όροι (MeSH): | Breast Neoplasms, Male*/therapy , Breast Neoplasms, Male*/pathology , Mastectomy*/trends , Mastectomy*/statistics & numerical data, Sentinel Lymph Node Biopsy/statistics & numerical data ; Sentinel Lymph Node Biopsy/trends ; Chemotherapy, Adjuvant/trends ; Chemotherapy, Adjuvant/statistics & numerical data ; Radiotherapy, Adjuvant/trends ; Radiotherapy, Adjuvant/statistics & numerical data ; Humans ; Male ; Australia ; Female ; New Zealand ; Middle Aged ; Aged ; Registries ; Adult ; Medical Audit |
| Περίληψη: | Purpose: Treatment of breast cancer in female patients has evolved over the past 20 years to improve outcomes, however it is unclear to what extent treatment has evolved in male patients. This bi-national registry observational study examined the disease burden and treatment landscape for new diagnoses of male breast cancer undergoing surgical management in Australia and New Zealand in comparison to females. Methods: A twenty-year study of male breast cancer patients compared to females was conducted for the period of 2003-2022 using the Breast Surgeons of Australia and New Zealand Quality Audit (BQA) database. Demographic, histological and treatment data was analysed according to biological sex and decade of breast cancer diagnosis (2003-2012 versus 2013-2022). Results: Data from 258,246 patients (1542 males, 256,704 females) were analysed. Treatment of male breast cancer was largely unchanged in the later decade compared to the earlier decade apart from sentinel lymph node biopsy uptake which was significantly higher in the later decade (66% vs 47%, p < 0.001). In contrast, significant differences in both surgical and adjuvant therapies were noted in the female group for every domain except post-mastectomy radiotherapy. Females treated early in the study period were associated with higher rates of adjuvant chemotherapy use than those treated in the later decade (OR 1.10, 95%CI 1.10; 1.11, p < 0.001), while adjuvant chemotherapy use was stable over time in the male group. Conclusions: In Australia and New Zealand there has been a de-escalation in axillary surgery for male breast cancer during the multimodality era. This evolution has been modest compared to the extensive changes in therapy for female breast cancer in line with formalised treatment guidelines. (Copyright © 2026 The Authors. Published by Elsevier Ltd.. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Stephen Kinsey-Trotman reports administrative support was provided by The University of Adelaide. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: Chemotherapy; De-escalation; Male breast cancer; Treatment; Treatment evolution |
| Entry Date(s): | Date Created: 20260728 Date Completed: 20260916 Latest Revision: 20260923 |
| Update Code: | 20260924 |
| PubMed Central ID: | PMC13446289 |
| DOI: | 10.1016/j.breast.2026.104887 |
| PMID: | 42520573 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1532-3080 |
|---|---|
| DOI: | 10.1016/j.breast.2026.104887 |